FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107116236> ?p ?o ?g. }

• W2107116236 endingPage "2672" @default.
• W2107116236 startingPage "2664" @default.
• W2107116236 abstract "This study was undertaken to determine the toxicities, pharmacokinetics, and maximum tolerated doses of oxaliplatin in patients with renal impairment and to develop formal guidelines for oxaliplatin dosing in this patient population.Thirty-seven adult cancer patients with variable renal function received intravenous oxaliplatin at 60 to 130 mg/m2 every 3 weeks. Patients were stratified by 24-hour creatinine clearance (CrCL) into four cohorts: group A (controls, CrCL > or =60 mL/min), group B (mild dysfunction, CrCL 40 to 59 mL/min), group C (moderate dysfunction, CrCL 20 to 39 mL/min), and group D (severe dysfunction, CrCL <20 mL/min). Doses were escalated in cohorts of three patients, and urine and plasma ultrafiltrates were assayed for platinum concentrations.No dose-limiting toxicities were observed in any patient group during the first cycle of therapy. Escalation of oxaliplatin to the maximum dose of 130 mg/m2 was well tolerated in all patient groups with a CrCL > or =20 mL/min (groups A, B, and C). Pharmacokinetic analysis showed that patients with decreased CrCL had a corresponding decrease in the clearance of plasma ultrafiltrable platinum (r2 = 0.765). However, oxaliplatin-induced side effects were not more common or severe in patients with mild to moderate renal dysfunction, despite the decrease in ultrafiltrable platinum clearance.Oxaliplatin at 130 mg/m2 every 3 weeks is well tolerated by patients with mild to moderate degrees of renal dysfunction. These data strongly support the recommendation that dose reductions of single-agent oxaliplatin are not necessary in patients with a CrCL greater than 20 mL/min." @default.
• W2107116236 created "2016-06-24" @default.
• W2107116236 creator A5003353558 @default.
• W2107116236 creator A5006594863 @default.
• W2107116236 creator A5006718606 @default.
• W2107116236 creator A5012143202 @default.
• W2107116236 creator A5024087470 @default.
• W2107116236 creator A5025976908 @default.
• W2107116236 creator A5028471294 @default.
• W2107116236 creator A5039967820 @default.
• W2107116236 creator A5041200743 @default.
• W2107116236 creator A5045286901 @default.
• W2107116236 creator A5045440420 @default.
• W2107116236 creator A5052340302 @default.
• W2107116236 creator A5054253771 @default.
• W2107116236 creator A5060084472 @default.
• W2107116236 creator A5060442605 @default.
• W2107116236 creator A5061705994 @default.
• W2107116236 creator A5064657905 @default.
• W2107116236 creator A5070251705 @default.
• W2107116236 creator A5072095266 @default.
• W2107116236 creator A5087941123 @default.
• W2107116236 date "2003-07-15" @default.
• W2107116236 modified "2023-09-30" @default.
• W2107116236 title "Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study" @default.
• W2107116236 cites W116550076 @default.
• W2107116236 cites W1570300525 @default.
• W2107116236 cites W1892571469 @default.
• W2107116236 cites W1924607323 @default.
• W2107116236 cites W1983134727 @default.
• W2107116236 cites W2000983373 @default.
• W2107116236 cites W2002975535 @default.
• W2107116236 cites W2009003896 @default.
• W2107116236 cites W2016333491 @default.
• W2107116236 cites W2017913687 @default.
• W2107116236 cites W2027610863 @default.
• W2107116236 cites W2032553799 @default.
• W2107116236 cites W2035088306 @default.
• W2107116236 cites W2051667118 @default.
• W2107116236 cites W2076668534 @default.
• W2107116236 cites W2085568318 @default.
• W2107116236 cites W2112182983 @default.
• W2107116236 cites W2116996913 @default.
• W2107116236 cites W2121368761 @default.
• W2107116236 cites W2311663614 @default.
• W2107116236 doi "https://doi.org/10.1200/jco.2003.11.015" @default.
• W2107116236 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12860942" @default.
• W2107116236 hasPublicationYear "2003" @default.
• W2107116236 type Work @default.
• W2107116236 sameAs 2107116236 @default.
• W2107116236 citedByCount "99" @default.
• W2107116236 countsByYear W21071162362012 @default.
• W2107116236 countsByYear W21071162362013 @default.
• W2107116236 countsByYear W21071162362014 @default.
• W2107116236 countsByYear W21071162362015 @default.
• W2107116236 countsByYear W21071162362016 @default.
• W2107116236 countsByYear W21071162362017 @default.
• W2107116236 countsByYear W21071162362018 @default.
• W2107116236 countsByYear W21071162362019 @default.
• W2107116236 countsByYear W21071162362020 @default.
• W2107116236 countsByYear W21071162362021 @default.
• W2107116236 countsByYear W21071162362022 @default.
• W2107116236 countsByYear W21071162362023 @default.
• W2107116236 crossrefType "journal-article" @default.
• W2107116236 hasAuthorship W2107116236A5003353558 @default.
• W2107116236 hasAuthorship W2107116236A5006594863 @default.
• W2107116236 hasAuthorship W2107116236A5006718606 @default.
• W2107116236 hasAuthorship W2107116236A5012143202 @default.
• W2107116236 hasAuthorship W2107116236A5024087470 @default.
• W2107116236 hasAuthorship W2107116236A5025976908 @default.
• W2107116236 hasAuthorship W2107116236A5028471294 @default.
• W2107116236 hasAuthorship W2107116236A5039967820 @default.
• W2107116236 hasAuthorship W2107116236A5041200743 @default.
• W2107116236 hasAuthorship W2107116236A5045286901 @default.
• W2107116236 hasAuthorship W2107116236A5045440420 @default.
• W2107116236 hasAuthorship W2107116236A5052340302 @default.
• W2107116236 hasAuthorship W2107116236A5054253771 @default.
• W2107116236 hasAuthorship W2107116236A5060084472 @default.
• W2107116236 hasAuthorship W2107116236A5060442605 @default.
• W2107116236 hasAuthorship W2107116236A5061705994 @default.
• W2107116236 hasAuthorship W2107116236A5064657905 @default.
• W2107116236 hasAuthorship W2107116236A5070251705 @default.
• W2107116236 hasAuthorship W2107116236A5072095266 @default.
• W2107116236 hasAuthorship W2107116236A5087941123 @default.
• W2107116236 hasConcept C112705442 @default.
• W2107116236 hasConcept C121608353 @default.
• W2107116236 hasConcept C126322002 @default.
• W2107116236 hasConcept C126894567 @default.
• W2107116236 hasConcept C159641895 @default.
• W2107116236 hasConcept C2777288759 @default.
• W2107116236 hasConcept C2780306776 @default.
• W2107116236 hasConcept C2780962732 @default.
• W2107116236 hasConcept C2908647359 @default.
• W2107116236 hasConcept C526805850 @default.
• W2107116236 hasConcept C71924100 @default.
• W2107116236 hasConcept C90924648 @default.
• W2107116236 hasConcept C99454951 @default.
• W2107116236 hasConceptScore W2107116236C112705442 @default.

• next